Distinct Sets of Genetic Alterations in Melanoma
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Exposure to ultraviolet light is a major causative factor in melanoma, although the relationship between risk and exposure is complex. We hypothesized that the clinical heterogeneity is explained by genetically distinct types of melanoma with different susceptibility to ultraviolet light. METHODS: We compared genome-wide alterations in the number of copies of DNA and mutational status of BRAF and N-RAS in 126 melanomas from four groups in which the degree of exposure to ultraviolet light differs: 30 melanomas from skin with chronic sun-induced damage and 40 melanomas from skin without such damage; 36 melanomas from palms, soles, and subungual (acral) sites; and 20 mucosal melanomas. RESULTS: We found significant differences in the frequencies of regional changes in the number of copies of DNA and mutation frequencies in BRAF among the four groups of melanomas. Samples could be correctly classified into the four groups with 70 percent accuracy on the basis of the changes in the number of copies of genomic DNA. In two-way comparisons, melanomas arising on skin with signs of chronic sun-induced damage and skin without such signs could be correctly classified with 84 percent accuracy. Acral melanoma could be distinguished from mucosal melanoma with 89 percent accuracy. Eighty-one percent of melanomas on skin without chronic sun-induced damage had mutations in BRAF or N-RAS; the majority of melanomas in the other groups had mutations in neither gene. Melanomas with wild-type BRAF or N-RAS frequently had increases in the number of copies of the genes for cyclin-dependent kinase 4 (CDK4) and cyclin D1 (CCND1), downstream components of the RAS-BRAF pathway. CONCLUSIONS: The genetic alterations identified in melanomas at different sites and with different levels of sun exposure indicate that there are distinct genetic pathways in the development of melanoma and implicate CDK4 and CCND1 as independent oncogenes in melanomas without mutations in BRAF or N-RAS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While these mutations are not UV-signature mutations20, they are more common in sun-exposed skin20–23.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language for Data Analysis and Graphics
Ihaka, R., & Gentleman, R. (1996) · Journal of Computational and Graphical Statistics · doi:10.1080/10618600.1996.10474713 · Cited by 11,220
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data
Dudoit, S., Fridlyand, J., & Speed, T. P. (2002) · Journal of the American Statistical Association · doi:10.1198/016214502753479248 · Cited by 2,672
Self-citationPinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo, W.-L., Chen, C., Zhai, Y., et al. (1998) · Nature Genetics · doi:10.1038/2524 · Cited by 2,240
Self-citationThe histogenesis and biologic behavior of primary human malignant melanomas of the skin.
Clark, W. H., From, L., Bernardino, E. A., & Mihm, M. C. (1969) · PubMed · Cited by 2,112
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Martin, M. A., Westfall, P. H., & Young, S. S. (1994) · Biometrics · doi:10.2307/2533464 · Cited by 1,699
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
LOWESS: A Program for Smoothing Scatterplots by Robust Locally Weighted Regression
Cleveland, W. S. (1981) · The American Statistician · doi:10.2307/2683591 · Cited by 1,150
Cited by
Items 801–900 of 1,006
Prognostic value of BRAF mutations in localized cutaneous melanoma
Nagore, E., Requena, C., Traves, V., Guillén, C., Hayward, N. K., Whiteman, D. C., & Hacker, E. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.10.064 · Cited by 48
The role of human endogenous retroviruses in melanoma
Singh, S., Kaye, S., Gore, M. E., McClure, M. O., & Bunker, C. B. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09415.x · Cited by 48
KRAS mutation testing in clinical practice
Perincheri, S., & Hui, P. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.986102 · Cited by 48
Shoushtari, A. N., Bluth, M. J., Goldman, D. A., Bitas, C., Lefkowitz, R. A., Postow, M. A., Munhoz, R. R., Buchar, G., Hester, R. H., Romero, J. A., et al. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000306 · Cited by 48
de la Cruz-Merino, L., Di Guardo, L., Grob, J.-J., Venosa, A., Larkin, J., McArthur, G. A., Ribas, A., Ascierto, P. A., Evans, J. T. R., Gomez-Escobar, A., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1246-0 · Cited by 44
Treatment Strategies and Survival Trends for Anorectal Melanoma: Is it Time for a Change?
Taylor, J. P., Stem, M., Yu, D., Chen, S. Y., Fang, S. H., Gearhart, S. L., Safar, B. A., & Efron, J. E. (2019) · World Journal of Surgery · doi:10.1007/s00268-019-04960-w · Cited by 48
Gallagher, S. J., Thompson, J. F., Indsto, J. O., Scurr, L. L., Lett, M., Gao, B.-F., Dunleavey, R., Mann, G. J., Kefford, R. F., & Rizos, H. (2008) · Neoplasia · doi:10.1593/neo.08702 · Cited by 49
Climent, J., García, J. L., Mao, J., Arsuaga, J., & Pérez‐Losada, J. (2007) · Biochemistry and Cell Biology · doi:10.1139/o07-072 · Cited by 49
Pérez‐Gómez, B., Aragonés, N., Gustavsson, P., Lope, V., López‐Abente, G., & Pollán, M. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08429.x · Cited by 48
The Spectrum of Spitz Melanocytic Lesions: From Morphologic Diagnosis to Molecular Classification
Cheng, T. W., Ahern, M. C., & Giubellino, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.889223 · Cited by 47
Melanoma in Non-Caucasian Populations
Stubblefield, J., & Kelly, B. C. (2014) · Surgical Clinics of North America · doi:10.1016/j.suc.2014.07.008 · Cited by 47
Novel Approaches in Melanoma Prevention and Therapy
Grimaldi, A. M., Cassidy, P. B., Leachman, S. A., & Ascierto, P. A. (2013) · Cancer treatment and research · doi:10.1007/978-3-642-38007-5_25 · Cited by 47
Bennani-Lahlou, M., Mateus, C., Escudier, B. J., Massard, C., Soria, J., Spatz, A., & Robert, C. (2008) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2008.04.016 · Cited by 47
Primary Anorectal Melanoma: An Update
Carcoforo, P., Raiji, M. T., Palini, G. M., Pedriali, M., Maestroni, U. V., Soliani, G., Detroia, A., Zanzi, M. V., Manna, A. L., Crompton, J. G., et al. (2012) · Journal of Cancer · doi:10.7150/jca.5187 · Cited by 47
The role of BRAF mutations in primary melanoma growth rate and survival
Mar, V., Liu, W., Devitt, B. A., Wong, S. Q., Dobrovic, A., McArthur, G. A., Wolfe, R. S., & Kelly, J. W. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13756 · Cited by 48
Restoring the tumour suppressive function of p53 as a parallel strategy in melanoma therapy
Lu, M. M., Miller, P. F., & Lü, X. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.05.008 · Cited by 47
Wilson, M. A., Zhao, F., Letrero, R., D'Andrea, K. P., Rimm, D. L., Kirkwood, J. M., Kluger, H. M., Lee, S. J., Schuchter, L. M., Flaherty, K. T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0093 · Cited by 47
Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review
Johnson, D. B., Peng, C., Abramson, R. G., Ye, F., Zhao, S., Wolchok, J. D., Sosman, J. A., Carvajal, R. D., & Ariyan, C. E. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0468 · Cited by 48
Najem, A., Krayem, M., Perdrix, A., Kerger, J. N., Awada, A. H., Journé, F., & Ghanem, G. (2017) · Anticancer Research · doi:10.21873/anticanres.12041 · Cited by 49
Genetic alterations in primary melanoma in Taiwan
Sheen, Y., Tan, K. T., Tse, K. ‐., Liao, Y., Lin, M., Chen, J., Liau, J., Tseng, Y., Lee, C., Hong, C. ‐., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18425 · Cited by 47
BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients
Dika, E., Veronesi, G., Altimari, A., Riefolo, M., Ravaioli, G. M., Piraccini, B. M., Lambertini, M., Campione, E., Gruppioni, E., Fiorentino, M., et al. (2019) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqz209 · Cited by 47
GNAQ and GNA 11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma
Livingstone, E., Zaremba, A., Horn, S., Ugurel, S., Casalini, B., Schlaak, M. S., Hassel, J. C., Herbst, R. A., Utikal, J. S., Weide, B., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18947 · Cited by 47
Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications
Vanni, I., Tanda, E. T., Dalmasso, B., Pastorino, L., Andreotti, V., Bruno, W., Boutros, A., Spagnolo, F., & Ghiorzo, P. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00172 · Cited by 47
Melnik, B. C., John, S. M., Carrera‐Bastos, P., & Schmitz, G. (2020) · Cancers · doi:10.3390/cancers12082111 · Cited by 48
Epidemiology and prevention of cutaneous melanoma
Demierre, M. (2006) · Current Treatment Options in Oncology · doi:10.1007/s11864-006-0011-z · Cited by 47
Selumetinib for the treatment of cancer
Ciombor, K. K., & Bekaii‐Saab, T. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.982275 · Cited by 47
Venesio, T., Chiorino, G., Balsamo, A., Zaccagna, A., Petti, C., Scatolini, M., Pisacane, A. M., Sarotto, I., Picciotto, F., & Risio, M. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.41 · Cited by 48
Clinicopathological Characteristics and Mutation Profiling in Primary Cutaneous Melanoma
Yaman, B., Akalın, T., & Kandiloğlu, G. (2014) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000000241 · Cited by 47
FADS2 function at the major cancer hotspot 11q13 locus alters fatty acid metabolism in cancer
Kothapalli, K. S. D., Park, H. G., Kothapalli, N. S. L., & Brenna, J. T. (2023) · Progress in Lipid Research · doi:10.1016/j.plipres.2023.101242 · Cited by 46
Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors
Mancini, M., & Yarden, Y. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.09.018 · Cited by 47
Uchiyama, R., Uhara, H., Uchiyama, A., Ogawa, E., Takazawa, Y., Ashida, A., Koga, H., Hayashi, K., Kiniwa, Y., & Okuyama, R. (2013) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2013.09.008 · Cited by 46
Ney, J. T., Froehner, S., Roesler, A., Buettner, R., & Merkelbach‐Bruse, S. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0176-oa · Cited by 46
Monnereau, A., Slager, S. L., Hughes, A. M., Smith, J. A., Glimelius, B., Habermann, T. M., Berndt, S. I., Staines, A. S., Norman, A. D., Cerhan, J. R., et al. (2014) · JNCI Monographs · doi:10.1093/jncimonographs/lgu004 · Cited by 48
FISH as an effective diagnostic tool for the management of challenging melanocytic lesions
Moore, M. W., & Gasparini, R. (2011) · Diagnostic Pathology · doi:10.1186/1746-1596-6-76 · Cited by 46
Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach
Davar, D., Tarhini, A. A., & Kirkwood, J. M. (2013) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2012.08.012 · Cited by 46
Biology and Treatment of BRAF Mutant Metastatic Melanoma
Kong, B. Y., Carlino, M. S., & Menzies, A. M. (2016) · Melanoma Management · doi:10.2217/mmt.15.38 · Cited by 46
Atypical Melanocytic Proliferations: A Review of the Literature
Ensslin, C. J., Hibler, B. P., Lee, E. H., Nehal, K. S., BUSAM, K. J., & Rossi, A. M. (2017) · Dermatologic Surgery · doi:10.1097/dss.0000000000001367 · Cited by 46
Self-citationCurrent and emerging systemic therapies for cutaneous metastatic melanoma
Mason, R., Au, L., Garces, A. I., & Larkin, J. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1601700 · Cited by 46
TERT promoter mutation is uncommon in acral lentiginous melanoma
Liau, J., Tsai, J., Jeng, Y., Chu, C., Kuo, K., & Liang, C. (2014) · Journal of Cutaneous Pathology · doi:10.1111/cup.12323 · Cited by 46
Lázár, V., Ecsedi, S., Szöllősi, A. G., Tóth, R., Vízkeleti, L., Rákosy, Z., Bégány, Á., Ádány, R., & Balázs, M. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.109 · Cited by 46
Clinical protein science in translational medicine targeting malignant melanoma
Gil, J., Betancourt, L. H., Pla, I., Sanchez, A., Appelqvist, R., Miliotis, T., Kuras, M., Oskolas, H., Kim, Y., Horvath, Z., et al. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09468-6 · Cited by 45
Delving into somatic variation in sporadic melanoma
Walia, V., Mu, E. W., Lin, J. C., & Samuels, Y. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.00976.x · Cited by 41
Differential roles of the pRb and Arf/p53 pathways in murine naevus and melanoma genesis
Ferguson, B., Konrad Muller, H., Handoko, H. Y., Khosrotehrani, K., Beermann, F., Hacker, E., Peter Soyer, H., Bosenberg, M., & Walker, G. J. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00752.x · Cited by 41
Conservation of Genetic Alterations in Recurrent Melanoma Supports the Melanoma Stem Cell Hypothesis
Sabatino, M., Zhao, Y., Voiculescu, S. E., Monaco, A., Robbins, P. F., Karai, L. J., Nickoloff, B. J., Maio, M., Selleri, S., Marincola, F. M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1939 · Cited by 46
The Biology and Clinical Development of MEK Inhibitors for Cancer
Luke, J. J., Ott, P. A., & Shapiro, G. I. (2014) · Drugs · doi:10.1007/s40265-014-0315-4 · Cited by 45
Current Status of Biological Therapies for the Treatment of Metastatic Melanoma.
Tang, T., Eldabaje, R., & Yang, L. (2016) · PubMed · Cited by 45
The new paradigm of systemic therapies for metastatic melanoma
Volpe, V. O., Klufas, D. M., Hegde, U. P., & Grant-Kels, J. M. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.04.1126 · Cited by 45
Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma
Zhang, X., Tang, J., Vergara, I. A., Zhang, Y., Szeto, P., Yang, L., Mintoff, C., Colebatch, A. J., McIntosh, L., Mitchell, K. A., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0407 · Cited by 45
Tavira, M., Mousavi-Khattat, M., Shakeran, Z., & Zarrabi, A. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123162 · Cited by 45
A phase II study of gefitinib in patients with metastatic melanoma
Patel, S. P., Kim, K. B., Papadopoulos, N. E., Hwu, W., Hwu, P., Prieto, V. G., Bar‐Eli, M., Zigler, M., Dobroff, A. S., Bronstein, Y., et al. (2011) · Melanoma Research · doi:10.1097/cmr.0b013e3283471073 · Cited by 45
Lipsker, D. M. (2006) · Archives of Dermatology · doi:10.1001/archderm.142.12.1638 · Cited by 45
Genitourinary melanoma: An overview for the clinician
DePalo, D. K., Elleson, K. M., Carr, M. J., Spiess, P. E., & Zager, J. S. (2022) · Asian journal of urology · doi:10.1016/j.ajur.2022.01.003 · Cited by 44
Spitz Nevus and Atypical Spitzoid Neoplasm
Miteva, M., & Lazova, R. Z. (2010) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2010.06.003 · Cited by 44
Progression of cutaneous melanoma: implications for treatment
Leong, S. P. L., Mihm, M. C., Murphy, G. F., Hoon, D. S. �., Kashani–Sabet, M., Agarwala, S. S., Zager, J. S., Hauschild, A., Sondak, V. K., Guild, V., et al. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9521-1 · Cited by 44
Hacker, E., Nagore, E., Cerroni, L., Woods, S. L., Hayward, N. K., Chapman, B. M., Montgomery, G. W., Soyer, H. P., & Whiteman, D. C. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.385 · Cited by 45
Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring
Klinac, D., Gray, E. S., Millward, M. J., & Ziman, M. R. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00054 · Cited by 44
Embryonic signaling in melanoma: potential for diagnosis and therapy
Strizzi, L., Hardy, K. M., Kirsammer, G. T., Gerami, P., & Hendrix, M. J. C. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.63 · Cited by 45
Maleka, A., Åström, G., Byström, P., & Ullenhag, G. J. (2016) · BMC Cancer · doi:10.1186/s12885-016-2657-7 · Cited by 44
Ardakani, N. M., Thomas, C., Robinson, C., Mina, K., Harvey, N. T., Amanuel, B., & Wood, B. A. (2017) · Pathology · doi:10.1016/j.pathol.2016.11.008 · Cited by 44
Neoadjuvant treatment for stage III and IV cutaneous melanoma
Gorry, C., McCullagh, L., O’Donnell, H., Barrett, S., Schmitz, S., Barry, M. G., Curtin, K., Beausang, E. S., Barry, R., & Coyne, I. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012974.pub2 · Cited by 44
HEDGEHOG/GLI-E2F1 axis modulates iASPP expression and function and regulates melanoma cell growth
Pandolfi, S., Montagnani, V., Lapucci, A., & Stecca, B. A. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.56 · Cited by 44
Controversial aspects of oncogene-induced senescence
Bianchi-Smiraglia, A., & Nikiforov, M. A. (2012) · Cell Cycle · doi:10.4161/cc.22589 · Cited by 38
New Perspectives on Melanoma Pathogenesis and Chemoprevention
Meyskens, F. L., Farmer, P. J., Yang, S., & Anton‐Culver, H. (2007) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-37696-5_16 · Cited by 44
Lasfar, A., & Cohen-Solal, K. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq155 · Cited by 44
Identification of new genes associated with melanoma: Novel genes as players in melanoma progression
Mauerer, A., Roesch, A., Hafner, C. M., Stempfl, T., Wild, P. J., Meyer, S., Landthaler, M., & VOGT, T. M. (2011) · Experimental Dermatology · doi:10.1111/j.1600-0625.2011.01254.x · Cited by 44
Distinct MHC gene expression patterns during progression of melanoma
Degenhardt, Y., Huang, J., Greshock, J. D., Horiates, G., Nathanson, K. L., Yang, X., Herlyn, M., & Weber, B. L. (2009) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20728 · Cited by 44
Jovanovic, B., Kröckel, D., Lindén, D., Nilsson, B. R., Egyházi, S., & Hansson, J. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.134 · Cited by 44
Hu, J., Wei, J., Yim, H., Wang, L., Xie, L., Jin, M. S., Kabir, M., Qin, L., Chen, X., Liu, J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01609 · Cited by 43
Clinical and histological features of head and neck melanoma: a population-based study in France
Dabouz, F., Barbe, C., Lesage, C., Clainche, A. L., Arnoult, G., Hibon, E., Bernard, P., & Grange, F. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13489 · Cited by 43
Using genetics and genomics strategies to personalize therapy for cancer: Focus on melanoma
Nathanson, K. L. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.017 · Cited by 44
Latimer, N. R., Abrams, K. R., Amonkar, M. M., Stapelkamp, C., & Swann, R. S. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0429 · Cited by 43
High frequency of PTEN mutations in nevi and melanomas from xeroderma pigmentosum patients
Masaki, T., Wang, Y., DiGiovanna, J. J., Khan, S. G., Raffeld, M., Beltaifa, S., Hornyak, T. J., Darling, T. N., Lee, C. R., & Kraemer, K. H. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12226 · Cited by 41
Identification of NTRK3 Fusions in Childhood Melanocytic Neoplasms
Wang, L., BUSAM, K. J., Benayed, R., Cimera, R., Wang, J., Denley, R. C., Rao, M., Aryeequaye, R., Mullaney, K. A., Cao, L., et al. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.11.005 · Cited by 43
Self-citationShikonin Inhibites Migration and Invasion of Thyroid Cancer Cells by Downregulating DNMT1
Zhang, Y., Sun, B., Huang, Z. L., Zhao, D., & Zeng, Q. (2018) · Medical Science Monitor · doi:10.12659/msm.908381 · Cited by 43
Ultraviolet radiation and cutaneous melanoma: a historical perspective
Autier, P., & Doré, J. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000609 · Cited by 43
Xu, L., Cheng, Z., Cui, C., Wu, X., Yu, H., Guo, J., & Kong, Y. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1987-z · Cited by 43
Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles
Williams, E. A., Shah, N., Montesion, M., Sharaf, R., Pavlick, D. C., Sokol, E. S., Alexander, B. M., Venstrom, J. M., Elvin, J. A., Ross, J. S., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-0510-7 · Cited by 43
Induction and transmission of oncogene-induced senescence
Rattanavirotkul, N., Kirschner, K., & Chandra, T. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03638-0 · Cited by 44
Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management
Sacco, A., Forgione, L., Carotenuto, M., Luca, A. D., Ascierto, P. A., Botti, G., & Normanno, N. (2020) · Cancers · doi:10.3390/cancers12102914 · Cited by 43
Biomarkers for Diagnosis, Prognosis and Response to Immunotherapy in Melanoma
Puglisi, R., Bellenghi, M., Pontecorvi, G., Pallante, G., Carè, A., & Mattia, G. (2021) · Cancers · doi:10.3390/cancers13122875 · Cited by 43
BRAFmutation testing in clinical practice
Ziai, J. M., & Hui, P. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.1 · Cited by 43
Thielmann, C. M., Chorti, E., Matull, J., Murali, R., Zaremba, A., Lodde, G. C., Jansen, P., Richter, L., Kretz, J., Möller, I., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.035 · Cited by 43
Microbiota, Oxidative Stress, and Skin Cancer: An Unexpected Triangle
Azzimonti, B., Ballacchino, C., Zanetta, P., Cucci, M. A., Monge, C., Grattarola, M., Dianzani, C., Barrera, G., & Pizzimenti, S. (2023) · Antioxidants · doi:10.3390/antiox12030546 · Cited by 43
Molecular Markers of Tumor Progression in Melanoma
Rother, J., & Jones, D. (2009) · Current Genomics · doi:10.2174/138920209788488526 · Cited by 43
Cockerell, C. J. (2012) · Dermatologic Clinics · doi:10.1016/j.det.2012.04.007 · Cited by 43
Practical application of new technologies for melanoma diagnosis
March, J., Hand, M., Truong, A., & Grossman, D. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.02.1140 · Cited by 43
Dual Suppression of the Cyclin-Dependent Kinase Inhibitors CDKN2C and CDKN1A in Human Melanoma
Jalili, A., Wagner, C., Pashenkov, M. V., Pathria, G., Mertz, K. D., Widlund, H. R., Lupien, M., Brunet, J.-P., Golub, T. R., Stingl, G., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs373 · Cited by 43
Wen, X., Ding, Y., Li, J., Zhao, J., Peng, R., Li, D., Zhu, B., Wang, Y., Zhang, X., & Zhang, X. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1989-8 · Cited by 44
Elder, D. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2504 · Cited by 43
Feng, Z., Wang, T., Su, X., & Guo, S. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.665222 · Cited by 42
Mao, L., Lian, B., Li, C., Bai, X. L., Zhou, L., Cui, C., Chi, Z., Sheng, X., Wang, X., Tang, B., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.1363 · Cited by 44
The 2023 WHO updates on skin tumors: advances since the 2018 edition
Fortarezza, F., Cazzato, G., Ingravallo, G., & Tos, A. P. D. (2024) · Pathologica · doi:10.32074/1591-951x-1006 · Cited by 42
Real-Time Raman Spectroscopy for Noninvasive in vivo Skin Analysis and Diagnosis
Zhao, J., Lui, H., David, I., & Zeng, H. (2010) · InTech eBooks · doi:10.5772/7603 · Cited by 44
MicroRNAs in the pathogenesis of malignant melanoma
Glud, M., & Gniadecki, R. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04579.x · Cited by 42
Long, G. V., Wilmott, J. S., Haydu, L. E., Tembe, V., Sharma, R., Rizos, H., Thompson, J. F., Howle, J., Scolyer, R. A., & Kefford, R. F. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12098 · Cited by 40
Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression
Scholtens, A., Foppen, M. H. G., Blank, C. U., van Thienen, J. V., van Tinteren, H., & Haanen, J. B. A. G. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.009 · Cited by 42
Ultraviolet exposure and risk of melanoma and basal cell carcinoma in Ulm and Dresden, Germany
Kaskel, P., Lange, U., Sander, S., Huber, M. A., Utikal, J. S., Leiter, U., Krähn, G. M., Meurer, M., & Kron, M. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12488 · Cited by 42
Distinct Sets of Genetic Alterations in Melanoma
THIERS, B. H. (2006) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70297-1 · Cited by 42
Toward a Molecular-Genetic Classification of Spitzoid Neoplasms
Tetzlaff, M. T., Reuben, A., Billings, S. D., Prieto, V. G., & Curry, J. L. (2017) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2017.05.003 · Cited by 42
Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling
Zou, Z., Ou, Q., Ren, Y., Lv, Q., Qin, L., Zhao, L., Su, S., Wu, X., Bao, H., Wang, A., et al. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12865 · Cited by 42
Metadata
- Authors
- Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., Pinkel, D., & Bastian, B. C.
- Affiliations
- University of California, San Francisco (US)
- Kumamoto University Hospital (JP)
- Memorial Sloan Kettering Cancer Center (US)
- Dermatopathologie Friedrichshafen (DE)
- Seoul National University (KR)
- Tohoku University (JP)
- University of Würzburg (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-17
- Volume
- 353
- Issue
- 20
- Pages
- 2135-2147
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1989121777
- Cited by
- 2,747
- References
- 38
- Citations by year
- 2026: 54 · 2025: 69 · 2024: 87 · 2023: 91 · 2022: 85 · 2021: 125 · 2020: 165 · 2019: 133 · 2018: 130 · 2017: 164 · 2016: 157 · 2015: 170 · 2014: 197 · 2013: 218 · 2012: 202
- FWCI
- 33.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Funders
- National Cancer Institute (R01CA094963, R33 CA95300, R33CA095300)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- melanoma, UV exposure, acral melanoma, mucosal melanoma, BRAF mutation, NRAS mutation, copy number alterations, CDK4, CCND1, oncogenes, tumor genetic heterogeneity, skin cancer
- MeSH terms
- Adult, Aged, Aged, 80 and over, DNA, Neoplasm, Environmental Exposure, Female, Humans, Male, Melanoma, Middle Aged, Mutation, Nucleic Acid Hybridization, Genes, ras, Risk Factors, Skin Neoplasms, Ultraviolet Rays, Signal Transduction, Genome, Human, Phosphatidylinositol 3-Kinases, Cyclin D1, Mitogen-Activated Protein Kinases, Proto-Oncogene Proteins B-raf, PTEN Phosphohydrolase, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.